Vanderbilt Memory and Alzheimer's Center, Vanderbilt University Medical Center, 1207 17th Ave S, Nashville, TN, 37212, USA.
Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, TN, USA.
Mol Neurodegener. 2021 Apr 29;16(1):29. doi: 10.1186/s13024-021-00452-5.
Alzheimer's disease (AD) is a progressive, neurodegenerative disorder that is characterized by neurodegeneration, cognitive impairment, and an eventual inability to perform daily tasks. The etiology of Alzheimer's is complex, with numerous environmental and genetic factors contributing to the disease. Late-onset AD is highly heritable (60 to 80%), and over 40 risk loci for AD have been identified via large genome-wide association studies, most of which are common variants with small effect sizes. Although these discoveries have provided novel insight on biological contributors to AD, disease-modifying treatments remain elusive. Recently, the concepts of resistance to pathology and resilience against the downstream consequences of pathology have been of particular interest in the Alzheimer's field as studies continue to identify individuals who evade the pathology of the disease even into late life and individuals who have all of the neuropathological features of AD but evade downstream neurodegeneration and cognitive impairment. It has been hypothesized that a shift in focus from Alzheimer's risk to resilience presents an opportunity to uncover novel biological mechanisms of AD and to identify promising therapeutic targets for the disease. This review will highlight a selection of genes and variants that have been reported to confer protection from AD within the literature and will also discuss evidence for the biological underpinnings behind their protective effect with a focus on genes involved in lipid metabolism, cellular trafficking, endosomal and lysosomal function, synaptic function, and inflammation. Finally, we offer some recommendations in areas where the field can rapidly advance towards precision interventions that leverage the ideas of protection and resilience for the development of novel therapeutic strategies.
阿尔茨海默病(AD)是一种进行性神经退行性疾病,其特征是神经退行性变、认知障碍和最终无法完成日常任务。阿尔茨海默病的病因复杂,许多环境和遗传因素都与该病有关。迟发性 AD 的遗传性很强(60%至 80%),通过大规模全基因组关联研究已经确定了 40 多个 AD 风险基因座,其中大多数是具有小效应量的常见变体。尽管这些发现为 AD 的生物学发病机制提供了新的见解,但仍缺乏能够改变疾病进程的治疗方法。最近,在阿尔茨海默病领域,抵抗病理学和对病理学下游后果的恢复力的概念引起了特别关注,因为研究继续发现即使进入老年也能逃避疾病病理学的个体以及具有 AD 所有神经病理学特征但逃避下游神经退行性变和认知障碍的个体。有人假设,从阿尔茨海默病风险到恢复力的重点转移提供了一个机会,可以揭示 AD 的新生物学机制,并为该疾病确定有前途的治疗靶点。这篇综述将重点介绍文献中报道的一些能够预防 AD 的基因和变体,并讨论它们的保护作用的生物学基础,重点是涉及脂质代谢、细胞运输、内体和溶酶体功能、突触功能和炎症的基因。最后,我们在该领域提出了一些建议,在这些领域可以快速推进精准干预措施,利用保护和恢复力的概念为开发新的治疗策略提供支持。